Suggestions
Anand Sivaraman
Director at Remidio Innovative Solutions
Professional Background
Anand Sivaraman is a prominent figure in the realm of healthcare technology, recognized for his innovative contributions, particularly in in vitro diagnostics and ophthalmology. Anand's professional journey is anchored in extensive academic accomplishments, having completed a Masters, PhD, and Post Doctoral research at the esteemed Massachusetts Institute of Technology (MIT). His expertise lies at the crucial intersection of clinical practice, engineering, and business development, enabling him to design and implement technologies that address real-world healthcare challenges.
As the Director at Remidio Innovative Solutions, Anand has played a pivotal role in launching device innovations that facilitate primary care delivery in both the United States and India. His belief that innovations must be economically viable informs his commitment to creating healthcare solutions that not only bridge the gap between basic sciences and engineering but also incorporate transformative business models. This approach has been validated through the successful deployment of Remidio's devices, which have gained traction in primary health centers across India.
Prior to his current role, Anand served in various capacities at ReaMetrix India Pvt Ltd, where he headed business development, engaged in product evangelism, and led hardware and assay development projects. His experience at ReaMetrix equipped him with a multifaceted understanding of product development, market intelligence, and innovative solution validation, all key to driving successful healthcare advancements. Anand's journey is not merely about technological progress; it also involves nurturing future innovators and leaders in healthcare, forming collaborations to establish an ecosystem that fosters entrepreneurship within the scientific and engineering communities.
Education and Achievements
Anand Sivaraman boasts a stellar educational background that underpins his expertise in healthcare technology. He earned his Doctor of Philosophy (PhD) in Chemical Engineering from the Massachusetts Institute of Technology, recognized globally for its cutting-edge research and academic rigor. Before this, he obtained a Bachelor of Technology (BTech) in Chemical Engineering from the prestigious Indian Institute of Technology, Kharagpur. This solid foundation in engineering has equipped Anand with the analytical and problem-solving skills essential to overcome the complex challenges within the healthcare sector.
Throughout his career, Anand has demonstrated a strong commitment to groundbreaking research and development. His work has not only led to innovative medical devices but has also addressed the essential aspect of affordability and scalability. By viewing the constraints of a developing nation as opportunities for innovation, Anand has championed the creation of solutions that are not only applicable in resource-limited settings but are also relevant to developed markets.
Achievements
Anand Sivaraman's dedication to healthcare innovation is reflected in a plethora of achievements throughout his career. At Remidio Innovative Solutions, he has overseen multiple successful device innovations that have been embraced by the healthcare community at large, facilitating improved healthcare access and service delivery. His strategic vision combines scientific innovation with practical application, addressing the critical need for affordability and accessibility in healthcare solutions.
In addition to his corporate accomplishments, Anand actively contributes to the broader scientific community. His prior role as a postdoctoral associate at MIT allowed him to participate in cutting-edge research that further enriched his expertise. Anand’s volunteer efforts with the Association for India's Development, Boston Chapter, highlight his commitment to impactful initiatives that align with his vision of promoting health equity through innovative technology solutions.
Anand is continuously seeking to partner with like-minded individuals who share his passion for fostering entrepreneurship and innovation. By creating collaborative environments that support scientists and engineers, he aims to empower the next generation of leaders capable of addressing pressing healthcare challenges.
In conclusion, Anand Sivaraman stands out as a visionary and a leader in healthcare technology, with a career characterized by a commitment to creating accessible, affordable, and innovative solutions. His educational background, coupled with his professional experiences, has established him as a key thought leader in the integration of engineering and healthcare practices. Anand's work not only enhances primary care delivery in diverse settings but also lays the groundwork for a more sustainable and equitable healthcare system globally.
Highlights
On this, World Sight Day, we wish to take a moment to raise awareness on the importance of an Annual Eye Exam, not only in preventing needless blindness, but as research clearly indicates - our eyes are windows to the live action of blood vessels, nerves and connective tissues throughout our body. In the comments, you will find a link from the American Academy of Ophthalmology, to 20 health conditions that an Eye Exam can surprisingly, catch.
Remidio has so far impacted nearly 10 million globally, with clinically validated, innovative medical devices, integrated with the power of offline Artificial Intelligence (AI). This has helped move testing to primary care centers, PHC's, FQHC's and even within the comfort of a patient's home.
This World Sight Day, we launch our new Corporate video, as we go beyond Preventing Needless Blindness, over the next 5 years, to now creating "Connected Care" models with our next set of device, biomarker and AI innovations. Do take a moment to watch the video!
Even as these are exciting times in Eye Research - we re-dedicate ourselves to achieving our new expanded core mission - that of bringing Specialist Care to Primary Care, thereby impacting 10X the number that we are able to impact today.
https://lnkd.in/gKMxGSqY
#HumanizingOphthalmicIntelligence #ConnectedCare #ArtificialIntelligence #Diabetes #diabeticretinopathy #glaucoma #AMD #ChronicKidneyDisease #Cardiovasculardisease #Nephropathy #Neuropathy #triaging #eyehealthindex #visualhealthindex #riskassessment #primarycare
https://lnkd.in/gEnRM3nK
We are happy to report an investment from SUN PHARMA, India's largest Pharmaceutical Company, into Remidio to help scale the public health impact of our products, globally.
Remidio 's portfolio of novel, portable and multimodal, ophthalmic medical devices, brings Comprehensive Eye Health assessment to Primary Care
More than 700 FQHCs, HRAs and primary care clinics in the US and 2500+ PHCs, Ophthalmology Clinics, Hospitals, Optical chains and Primary Care clinics in India, use our novel devices with integrated offline Artificial Intelligence (AI) algorithms / teleophthalmology connect, that have so far helped impact more than 7.5M patients globally, through early detection of eye diseases.
With this investment, we seek to scale deployment of our current product solutions globally, and also invest into the Research and Development of new products, that help us go beyond screening just for eye health - specifically screening for systemic risks, including cardiovascular health.
We thank the thousands of public health personnel, primary care doctors, clinical research partners and ophthalmologists who have helped us through the years, in shaping our vision and purpose, as an organization
Lastly, a shout out to everyone at Remidio in Bangalore, Singapore and the US, as well as ex-Remidians for the deep sense of purpose behind everything we do, our E3C3 culture, and for all the hard work that goes into achieving our goal of preventing needless blindness !
Collectively, we are excited about the opportunity to re-shape Eye Health, even as we understand the responsibility that we now carry to execute on our vision, to impact our central stakeholder - the customer needing access to eye screening !
Pramod K K Rajesh Rai Mark Wang Manish Kumar B Jayakumar A R Rajat K. Dr Prem Kumar Nair Dr Prem Pillay FACS(USA) Zubin Daruwalla Deepak Darda suresh A. Deepanwita Chattopadhyay Shridhar Lolla Srinivasa Bharathy Jason Jong Tuck Kan Woo Vikram Vuppala Swagatam Biswas Amogh Mayekar IKP Knowledge Park KITVEN FUND Pureland Global Venture
Wilson D Souza Divya Rao Shweta B. Bhargav Sosale Ronnie Dutta Florian Savoy Erik Hafkey Sundeep Agarwal Vasudev Purohit
#eyehealth #publichealth #primarycare #comprehensive #eyehealthindex (EHI) #purpose #preventableblindness #E3C3 #visionimpairment #ai #medtech #sunpharma #remidio
